IL-17A Blockade Halts Damage to Spine in AS (CME/CE)

(MedPage Today) -- Over 2 years, 80% of patients with ankylosing spondylitis treated with secukinumab had no progression
Source: MedPage Today Meeting Coverage - Category: Journals (General) Source Type: news